Compare Abeona Therapeutics Inc (ABEO) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Zeta Global Holdings Corp — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Zeta Global Holdings Corp trades at $21.17 (market cap $5.45B). The key difference: Zeta Global Holdings Corp is far larger — about 14.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Zeta Global Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | ZETA | |
|---|---|---|
Market Cap | $373.32M | $5.45B |
Sector | Health | Technology |
52-Week High | $7.23 | $25.24 |
52-Week Low | $4.17 | $14.00 |
Enterprise Value | $228.22M | $5.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ZETA trades at $21.82, up 5.46% over the past 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $27.50. Recent earnings beats and a strategic AI partnership with Palantir highlight strong operational momentum, though negative net income and cash flow remain concerns. The stock shows robust revenue growth and high gross margins, supported by positive media coverage and institutional interest.
The outlook for ZETA is cautiously optimistic, driven by AI integration and consistent earnings outperformance. Key risks include persistent unprofitability and competitive pressures in the marketing technology sector. Investors should weigh the high valuation multiples against growth potential, with analyst sentiment strongly favoring buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
